The 28th EADV Congress brought innovations to dermatologists in many respects. In this overview, we have attempted to be balanced and to focus on the presentations which are practically relevant. The new insights into the pathogenesis of inflammatory skin diseases have provided biomarkers that are becoming significant to dermatology. Introduction of new treatments in inflammatory dermatoses requires a critical and adequate positioning of new treatments in daily practice.
In particular in psoriasis, the innovations found their way to real clinical practice: In children with psoriasis anti-IL-17 are currently explored. On ixekizumab, 78% of children with psoriasis reached a PASI 90 response. Comorbidities are also relevant to psoriasis. Studies on the efficacy of trea...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Less exacerbations with azithromycin maintenance in primary ciliary disease Next Article
No hint of teratogenicity through ixekizumab »
Table of Contents: EADV 2019
Spotlight on Psoriasis
New Insights in Photoprotection
Rosacea – from new spectrum to new therapy
Best of the Posters
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.